MapLight Therapeutics, Inc. Investing Cash Flow
MapLight Therapeutics, Inc. (MPLT) reported Investing Cash Flow of $127.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- MapLight Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $60.70M, a 248.19% increase year-over-year.
- MapLight Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $67.01M, a 78.69% increase year-over-year.
- MapLight Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$242.55M, a 848.76% decline year-over-year.
- MapLight Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$135.59M.
- MapLight Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$323.21M.
- MapLight Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$80.79M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $127.71M 10-Q · filed 2026-08-13 | -$114.84M derived: sum of 3 quarters · filed 2026-08-13 | -$250.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $67.01M 10-Q · filed 2026-05-14 | -$175.55M derived: sum of 2 quarters · filed 2026-05-14 | -$311.13M derived: sum of 3 quarters · filed 2026-05-14 | -$293.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$242.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$378.14M derived: sum of 2 quarters · filed 2026-03-26 | -$360.71M derived: sum of 3 quarters · filed 2026-08-13 | -$323.21M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$135.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-04 | -$118.15M derived: sum of 2 quarters · filed 2026-08-13 | -$80.65M 10-Q · filed 2025-12-04 | -$48.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $17.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $54.93M 10-Q · filed 2026-08-13 | $87.33M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $37.50M 10-Q · filed 2026-05-14 | $69.89M derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $32.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$80.79M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$113.18M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |